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Abstract
The transcription factor Brn3a, product of the pou4f1 gene, is expressed in most sensory neurons throughout
embryogenesis. Prior work has demonstrated a role for Brn3a in the repression of early neurogenic genes; here we
describe a second major role for Brn3a in the specification of sensory subtypes in the trigeminal ganglion (TG).
Sensory neurons initially co-express multiple Trk-family neurotrophin receptors, but are later marked by the unique
expression of TrkA, TrkB or TrkC. Maturation of these sensory subtypes is known to depend on the expression of
Runx transcription factors. Newborn Brn3a knockout mice fail to express TrkC, which is associated in the TG with
mechanoreceptors, plus a set of functional genes associated with nociceptor subtypes. In embryonic Brn3a
-/- gang-
lia, the normal expression of Runx3 is never initiated in TrkC
+ neurons, and Runx1 expression is greatly attenuated
in TrkA
+ nociceptors. These changes are accompanied by expanded expression of TrkB in neurons that abnormally
express multiple Trks, followed by the loss of TrkC and TrkA expression. In transgenic embryos expressing a Brn3a-
VP16 dominant transactivator, Runx3 mRNA expression is increased, suggesting that it is a direct regulatory target
of Brn3a. Chromatin immunoprecipitation confirms that Brn3a binds in vivo to a conserved upstream enhancer ele-
ment within histone H3-acetylated chromatin in the Runx3 locus. Together these data show that Brn3a acts
upstream of the Runx factors, which then repress TrkB expression to allow establishment of the non-overlapping
Trk receptor profiles and correct terminally differentiated phenotypes.
Background
Sensory neurons of the dorsal root ganglia (DRG) and
trigeminal ganglia (TG) convey somatosensory informa-
tion to the spinal cord and brainstem. During embryonic
development, sensory neurons differentiate into three
primary subtypes: nociceptors (pain), mechanoreceptors
(touch), and proprioceptors (muscle tension). In the
DRG, these are characterized by the expression of the
neurotrophin receptors TrkA, TrkB and TrkC, respec-
tively. In the TG, proprioceptors for the muscles of mas-
tication reside in the mesencephalic trigeminal (mesV)
within the central nervous system, and TrkC is
expressed in subsets of mechanoreceptors [1]. In perina-
tal development, nociceptors further differentiate into
peptidergic and non-peptidergic phenotypes, the latter
being distinguished by downregulation of TrkA and
expression of Ret [2,3].
Sensory neurogenesis is dependent on the expression
of the basic helix-loop-helix (bHLH) transcription fac-
tors Neurog1 and Neurog2 [4,5]. Mice lacking Neurog2
fail to generate early-born DRG proprioceptors, an effect
that is later compensated by Neurog1, while mice lack-
ing both Neurog factors show global failure in sensory
neurogenesis [6]. The subsequent specification of DRG
proprioceptors and nociceptors is dependent on the
runt-domain transcription factors Runx3 and Runx1,
which maintain and refine the expression of Trk recep-
tors, and lead to the expression of subtype-specific func-
tional genes and correct innervation of central nervous
system targets [7,8].
Beginning just prior to cell cycle exit, nearly all
embryonic sensory neurons co-express the POU-homeo-
domain transcription factor Brn3a and the LIM-homeo-
domain factor Islet1 [9]. Sensory neurons lacking these
factors exhibit multiple defects in sensory axon growth,
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TG, Brn3a facilitates the progression of sensory develop-
ment by terminating the expression of neurogenic
bHLH factors by direct repression [13,14], and a similar
role has been described for Islet1 [15], defining one
common function for these pan-sensory factors.
It is less clear what role Brn3a plays in defining sen-
sory subtypes. Although pan-sensory transcription fac-
tors are not obvious candidates for subtype
specification, previous studies have shown dispropor-
tionate loss of some subtype markers in the Brn3a
knockout [16-18], and Islet1 knockout DRG exhibit a
loss of nearly all nociceptors in the developing ganglia,
while TrkC
+ proprioceptors are relatively spared [15].
Here we demonstrate a role for Brn3a in subtype spe-
cification during TG development. At birth, the TG of
Brn3a
-/- mice exhibit a profound loss of TrkC, Runx3,
and multiple nociceptor channels and receptors, while
sensory neuropeptide expression is maintained. During
embryogenesis, Brn3a is required to initiate normal
expression of the fate selector genes Runx3 and Runx1.
At midgestation, Brn3a
-/- TG show expanded TrkB
expression compared to wild type, resulting in failure to
segregate TrkB
+ from TrkC
+ and TrkA
+ neurons, effects
that are consistent with the loss of Runx function. Chro-
matin immunoprecipitation demonstrates that Brn3a
interacts with a Runx3 upstream enhancer in vivo,
revealing the first direct positively regulated Brn3a tar-
get. Together these data show that Brn3a creates a per-
missive condition for the expression of the Runx factors,
which then repress TrkB expression and allow differen-
tiation of the principal sensory subtypes.
Methods
Animals and matings
Mice carrying a Brn3a null allele [10] or a TauLacZ
transgene replacing the Brn3a coding sequence [19]
have been previously described, and mice heterozygous
for these alleles were maintained in a C57bl/6 back-
ground. For timed matings, noon of the day on which
mucous plugs were identified was designated embryonic
day 0.5 (E0.5). The age of harvested embryos was con-
firmed using morphological criteria and body length
[20]. Embryos expressing a Brn3a-VP16 dominant trans-
activator in sensory ganglia were generated by trans-
genic expression of a construct containing a VP16
activation domain fused to sequences encoding the car-
boxy-terminal 238 amino acids of Brn3a, including the
POU-specific and POU-homeodomains. Brn3a-VP16
was expressed under control of an 11-kb Brn3a sensory
enhancer/promoter, in which the native sequences med-
iating Brn3a binding have been mutated to eliminate
negative autoregulation [21].
Immunofluorescence and in situ hybridization
Embryos for immunofluorescence and in situ hybridiza-
tion studies were generated by timed matings as
described above. Embryos were fixed by immersion in
4% paraformaldehyde for 30 minutes (E10.5) or 2 hours
(E13.5). Newborn pups were fixed by transcardiac perfu-
sion with 4% paraformaldehyde; the cranium was then
opened and the brain was post-fixed 2 hours in the
same fixative. Tissue was embedded in Neg50 (Thermo
Fisher, Waltham, MA, USA) and sectioned on a cryo-
stat. Slides were incubated overnight at 4°C in primary
antisera, washed then incubated with Alexa 488 or 594
dye-conjugated secondary antibodies (Invitrogen, Carls-
bad CA, USA) for 1 hour at room temperature and
mounted in Vectashield (Vector Laboratories, Burlin-
game, CA, USA). Polyclonal rabbit antiserum against
Brn3a has been previously described [22]. Other antisera
used included rabbit antisera against Etv1/Er81, Runx1
and Runx3 obtained from Dr Sylvia Arber [23,24], rabbit
antisera against TrkA obtained from Dr Louis Reichardt,
and guinea pig antisera against Islet2 obtained from Dr
Sam Pfaff [25]. Immunofluorescence for other antigens
was performed with commercially available antibodies,
including goat antisera against TrkB and TrkC (R&D
Systems, Minneapolis, MN, USA), rabbit antiserum
against TrkB (Cell Signaling, Danvers, MA, USA), goat
antiserum against cRET (Fitzgerald, Acton, MA, USA)
goat antiserum against LacZ (Biogenesis/MorphoSys,
Kingson, NH, USA) and rabbit antiserum against Islet1
(Abcam, Cambridge, MA, USA).
In situ hybridization was performed on cryostat sec-
tions using digoxigenin labeled cRNA probes as pre-
viously described [26]. In situ hybridization probes for
peptidergic and non-peptidergic sensory markers were
gifts of Qiufu Ma and have been previously described
[7,27]. A cDNA encoding Htr3a was a gift of Allan Bas-
baum [28].
Luciferase transfection assays
Transient transfections for luciferase activity assays were
performed in CV-1 epithelial cells by lipofection. Luci-
ferase reporter constructs for transfection assays con-
tained three copies of a Brn3a recognition site linked to
a minimal promoter derived from the rat prolactin gene
in the vector pGL-2 [29]. The oligonucleotide sequences
used to make the reporter construct for the consensus
Brn3a recognition element were GATCTCTCCTGCA-
TAATTAATTACGCCCG and GATCCGGGCGTAAT-
TAATTATGCAGGAGA (core binding site in italics).
An effector plasmid consisting of a VP16 activation
domain fused to Brn3a, identical to that used for the
transgenic misexpression of VP16-Brn3a, was con-
structed in the expression vector pcDNA1-amp. Lucifer-
ase assays were performed as previously described [30].
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For the generation of Brn3a
+/+ and Brn3a
-/- TG samples,
Brn3a heterozygote mice were mated and the embryos
were harvested at E13.5. Transgenic founder animals
carrying the Brn3a-VP16 construct were also dissected
at E13.5. TG were removed by blunt dissection and
carefully freed of adherent non-neural tissue with fine
forceps. Dissected ganglia were placed in RNAse inhibi-
tor solution (RNAlater, Ambion, Austin, TX, USA), and
RNA was prepared using the RNeasy system (Qiagen,
Valencia, CA, USA). Embryos were genotyped for Brn3a
alleles using quantitative PCR from a sample of tail or
hind-limb tissue harvested at the time of ganglion dis-
section. For analysis of Brn3a knockout and control
ganglia, TG from five embryos were pooled for a single
microarray analysis. For analysis of VP16-Brn3a trans-
genic ganglia, RNA was prepared from a pair of TG
from a single E13.5 embryo, yielding 0.5 to 1.0 μgo f
R N A .T h r e eV P 1 6 - B r n 3 aa n dt h r e el i t t e r m a t ec o n t r o l
samples were harvested, allowing a total of nine semi-
independent comparisons between VP16 and control
s a m p l e s .T h eV P 1 6 - B r n 3 am i c r o a r r a yr e s u l t sw e r et h e n
compared to the ranked lists of transcripts increased
and decreased in the E13.5 Brn3a
-/- ganglia to identify a
subset of these changes that may indicate direct targets
(Additional file 1). The microarray analyses of Brn3a
-/-
and control ganglia used for comparison purposes
appear in detail elsewhere [31].
The generation of cDNA, production of labeled cRNA
with a single T7 amplification step, and hybridization to
GeneChip arrays were all performed according to stan-
dard protocols provided by the manufacturer (Affyme-
trix, Santa Clara, CA, USA). Gene expression analysis
was performed using the Affymetrix 430v2 array. The
primary analysis of microarray data, including determi-
nation of the absence/presence of the assayed tran-
scripts, transcript expression levels, and the probability
of change in transcript expression between samples
(’change P’) was performed with Microarray Suite 5.0
(MAS5, Affymetrix). Default MAS5 parameters were
used for increase (I) and decrease (D) calls, which were
P < 0.002 and P > 0.998 for I and D, respectively. All
array values were scaled to a target value of 500 using
global scaling. Microarray probe sets were related to the
corresponding mouse transcripts using the NetAffx
database (Affymetrix), based on the NCBI Build 36
annotation of the mouse genome.
Electrophoretic mobility gel shift assays
Recombinant Brn3a protein was produced by transfect-
ing HEK293 cells with a plasmid containing the full cod-
ing sequence of Brn3a in the vector pcDNA1-amp using
Lipofectamine 2000 (Invitrogen). Cells were suspended
in a high-salt extraction buffer containing 20 mM
HEPES pH7.9, 25% glycerol, 450 mM NaCl and 0.2 mM
EDTA. Protease inhibitors were added from the Com-
plete Mini tablet (Roche Applied Science, Indianapolis,
IN, USA) and cells lysed by sonication. Cellular debris
was removed by centrifugation and the resulting super-
natant protein extract was collected.
Synthetic double-stranded oligonucleotide probes that
varied in length from 39 to 79 bp were end-labeled with
g
32P by polynucleotide kinase (New England Biolabs,
Beverly, MA, USA). Brn3a protein HEK cell lysate or
control untransfected cell lysate was incubated with the
probe for 20 minutes in a binding buffer consisting of
20 mM Tris, pH 8.0, 100 mM KCl, 5 mM MgCl2 ,0 . 2
mM EDTA, 100 mg/ml poly(dI-dC), 100 mg/ml bovine
serum albumin, 10% glycerol and 1 mM DTT. Polyclo-
nal rabbit anti-Brn3a antiserum was added to some
samples prior to gel loading to obtain an antibody
supershifted band. Electrophoresis was performed on a
5% polyacrylamide gel (Biorad, Hercules, CA, USA). The
sequences of all oligonucleotide probes used in the elec-
trophoretic mobility gel shift assay (EMSA) are listed in
Additional file 2.
Chromatin immunoprecipitation
The consensus binding site of Brn3a and conserved var-
iants of this sequence that permit high affinity binding
have been previously determined [29]. Candidate Brn3a
binding sites corresponding to these sequences in the
Runx3 locus and other potential target gene loci were
determined using the search functions of Lasergene
(DNAstar, Madison, WI, USA). Cross-species sequence
conservation within the Runx3 locus was analyzed using
the UCSC genome browser.
Methods for chromatin immunoprecipitation (ChIP)
have been previously published [14]. Briefly, trigeminal
ganglia were dissected from E13.5 wild-type ICR mouse
embryos. Proteins were fixed to DNA by formaldehyde
treatment and DNA was sonicated to an average size of
500 bp. Selection was performed using either a polyclonal
rabbit antibody to Brn3a [22] or a polyclonal rabbit anti-
body to acetylated histone H3 (Upstate Biotechnology/
Millipore, Billerica, MA, USA) bound to an anti-rabbit
IgG magnetic bead (Invitrogen, Carlsbad CA, USA). Two
or three quantitative PCR primers encompassing approxi-
mately 70-bp amplicons were designed to sequences close
to each of the identified potential binding sites. Quantita-
tive PCR was performed using an Applied Biosystems
(Foster City, CA, USA) 7300 thermocycler and enrichment
of the selected chromatin relative to an unselected control
sample was analyzed by the cycle threshold difference
method [32]. A baseline (one-fold enrichment) for data
normalization was set using control primers against a
region of the Alb (serum albumin) locus that is not tran-
scribed in sensory neurons and does not contain Brn3a
binding sites [14]. The sequences of all primers used in
the ChIP assay are listed in Additional file 3.
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Brn3a expression is maintained in all sensory subtypes
throughout embryogenesis
In prior studies we have shown that Brn3a is expressed
in all or nearly all trigeminal precursors at midgestation
[9,26]. To determine whether Brn3a expression is main-
tained in all of the principal neuronal subtypes in the
TG, we examined the TG of pups at postnatal day 0.5
(P0), the last day on which Brn3a knockout mice are
viable. We found that Brn3a is co-expressed with the
pan-sensory transcription factor Islet1 at this stage,
although the relative signals for the two proteins vary
(Figure 1A). Brn3a was also co-expressed with markers
for the principal sensory subtypes, including the nerve
growth factor receptor TrkA (Figure 1B), the brain-
derived neurotrophic factor and neurotrophin-4 receptor
TrkB (Figure 1C), the neurotrophin-3 receptor TrkC
(Figure 1D) and the glial cell line-derived neurotrophic
factor receptor RET (Figure 1E). Thus, it is plausible
that Brn3a may play a role in the development of multi-
ple subtypes of trigeminal neurons.
Cell death is limited in the Brn3a knockout
Prior studies have reported significant cell loss in the sen-
sory ganglia of Brn3a knockout mice. Huang et al.[ 1 8 ] ,
using Nissl staining, reported that 29% of total TG neu-
rons remained at P0. Lei et al.[ 3 3 ] ,u s i n gt h en e u r o n a l
marker NeuN, reported 31% of neurons remaining,
whereas Xiang et al. [10] reported reduction of the cross-
sectional area of the Brn3a
-/- TG to 56% of controls. In
order to clearly distinguish changes in cell fate from the
complete absence of a significant fraction of sensory neu-
rons, we first determined whether the Brn3a
-/- TG was
normal in size and cellularity in our samples at E13.5 and
P0.5. Islet1 was employed as a specific nuclear marker for
sensory neurons because its expression does not change
in Brn3a knockout ganglia. At E13.5 there was no appar-
ent difference between the size of the TG in Brn3a
tLacZ/+
and Brn3a
tLacZ/- embryos (Figure 1F, G). Immunofluores-
cence for Islet1 showed clear nuclear outlines in Brn3a-
tLacZ/- ganglia (Figure 1H), and measurement of the
cross-sectional area of the trigeminal at E13.5 showed no
significant difference between heterozygous and knock-
out embryos (Figure 1I), consistent with prior studies
[12,18]. At P0, Islet1 staining and nuclear morphology
remained normal, although there was a marked distur-
bance in the appearance of labeled axonal fibers within
the ganglion (Figure 1J, K). Compared to prior studies,
we observed a more modest loss of TG neurons, concen-
trated in the rostral pole of the ganglion, and we found
that approximately 72% of the normal complement of
TG neurons were present at birth in the Brn3a knockout
(Figure 1L). Potential reasons for the differing results
appear in the Discussion.
TrkC, Runx3 and nociceptor markers are selectively lost in
the Brn3a knockout
We next examined markers of sensory subtypes in the
T Go fB r n 3 ak n o c k o u tm i c ea tP 0 ,t h el a s ts t a g et h a t
could be examined owing to the neonatal death of the
mutants (Figure 2). In the DRG, proprioceptors co-
express TrkC and Runx3 [34], and Ia somatic muscle
afferents also express ETV1 [35], but this population
appears to be absent from the trigeminal [13] because
the corresponding proprioceptors innervating the mus-
cles of mastication are located in the mesencephalic tri-
geminal (mesV). In the TG, at least some of the TrkC-
expressing neurons are mechanoreceptors [1]. As
expected, TrkC and Runx3 were co-expressed in a
population of large diameter cells in the wild-type gang-
lion (Figure 2A). Consistent with prior observations
[11,18], we observed an almost complete loss of TrkC in
the Brn3a knockout, and Runx3 expression was also
nearly absent (Figure 2B). ETV1 was observed in a
population of small diameter cells in the trigeminal.
These cells were negative for TrkC (Figure 2C) but co-
expressed Islet2 (Figure 2E), which together with their
small size suggests that they are not proprioceptors.
ETV1 expression in these neurons was largely unaf-
fected by loss of Brn3a (Figure 2D, F).
I nt h ew i l d - t y p eg a n g l i o nw eo b s e r v e de x p r e s s i o no f
TrkB in a population of large diameter cells (Figure 2G).
Relatively little is known about the sensory modalities
characterized by TrkB expression, but these cells are
likely to include mechanoreceptors such as Ruffini affer-
ents and Pacinian corpuscles [36,37]. Expression of
TrkB was maintained in the knockout, but with a
marked shift in the localization of the antigen from the
cell body to axons within the ganglion (Figure 2H). The
persistence of detectable TrkB expression at P0 was
confirmed by in situ hybridization (Additional file 4).
Thus, TrkB mechanoreceptors appear to be specified in
the Brn3a knockout, but their development is abnormal.
Prior work has shown that nociceptors are identified
by expression of several markers in a complex and chan-
ging pattern. Early in development all nociceptors co-
express TrkA and Runx1, while in postnatal develop-
ment the non-peptidergic subset of nociceptors downre-
gulate TrkA and begin to express Ret along with Runx1.
Peptidergic neurons maintain expression of TrkA, lose
Runx1 expression, and never express Ret [2,7,38]. Due
to perinatal lethality, only the initial part of this process
could be examined in Brn3a knockouts.
In the Brn3a knockout TG we observed a marked
reduction in the level of Runx1 expression (Figure 2I, J),
and the number of cells positive for Runx1 was reduced
by an average of 64% across the extent of the ganglion
(Figure 2K). Correction for cell loss using Islet1 to
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that the proportion of cells in the ganglion positive for
R u n x 1w a sr e d u c e df r o m3 4±3 %t o1 8±3 %( F i g u r e
2L), demonstrating a specific reduction in Runx1
expression in the absence of Brn3a.
The TG of newborn Brn3a
-/- mice also exhibited
changes in the expression of the sensory subtype mar-
kers TrkA and Ret. The number of TrkA
+ neurons was
markedly reduced at P0 (Figure 2M, N), consistent with
previous reports [18,39]. In contrast, abundant Ret
+ neu-
rons persisted in the Brn3a
-/- TG (Figure 2P, R). Ret is
expressed in non-peptidergic nociceptors, which initially
co-express TrkA [38], and also in earlier-developing
neurons with large cell bodies, which are likely to
include certain classes of mechanoreceptors [40]. In the
Brn3a
-/- TG at P0 the persisting Ret
+ neurons appear to
belong to the latter class, in that they have large cell
bodies, and do not co-express Runx1 (Figure 2O, P), or
Figure 1 Pan-sensory expression of Brn3a and survival of a majority of trigeminal neurons in Brn3a knockout mice. (A-E) Co-
localization of Brn3a with specific sensory markers in the TG in transverse sections of P0 wild-type ganglia. Brn3a is co-localized with the pan-
sensory marker Islet1 and the subtype-specific markers TrkA, TrkB, TrkC, and Ret. (F-I) Islet1 expression and LacZ expressed from the Brn3a locus
(Brn3a
tLacZ allele) were used to assess TG morphology and marker expression at E13.5. Ganglion morphology is grossly normal (F, G), and Islet1
continues to be expressed in LacZ
+ neurons in Brn3a knockout embryos (H). No significant difference in the volumes of Brn3a
tLacZ/- and
Brn3a
tLacZ/+ control TG was observed at this stage (I). The zero coordinate is the rostral pole of the ganglion. Paired T test for comparison of
coronal section areas across the rostrocaudal extent of the ganglion: n = 8, P = 0.12, not significant. (J-L) At P0.5 Islet1 expression continued to
identify all or nearly all LacZ
+ neurons in Brn3a
tLacZ/- knockout and Brn3a
tLacZ/+ control TG (J, K, transverse section). Islet1 immunoreactive nuclei
were counted in serial sections across the rostrocaudal extent of the TG (L), and mean cell number was reduced from 696 to 501 nuclei per
section (72% remaining), with cell loss concentrated in the rostral pole of the ganglion. Paired T-test for comparison cell number in matched
coronal sections across the entire rostrocaudal extent of the ganglion: n = 12, P = 0.01. 5 g, trigeminal ganglion; 9 g, geniculate ganglion; Di,
diencephalon; Hb, hindbrain; HT, heterozygote control; KO, knockout; Ot, otic region.
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+/Runx1
- neurons express Brn3a (Figure 1E), they do
not require it for survival, or for Ret expression.
Brn3a is required for the expression of a battery of
Runx1-dependent nociceptor markers
Nociceptors can be classified by the expression of pep-
tides such as substance P, calcitonin gene related pep-
tide (CGRP) and somatostatin, and a variety of receptors
and channels that function in pain reception and trans-
mission, including G-protein coupled receptors, such as
opioid receptors and Mas1-related receptors (Mrgs),
cation channels of the transient receptor potential (Trp)
family, and the tetrodotoxin-resistant sodium channels
Scn10a/Nav1.8 and Scn11a/Nav1.9 [2]. Many of the
receptors and channels that mediate nociceptor function
in the DRG are dependent on Runx1, while the sensory
Figure 2 Loss of Brn3a profoundly affects the major sensory subtypes at birth. Expression of markers of known sensory subtypes were
examined at P0 in transverse sections of Brn3a knockout and heterozygote control TG. Heterozygote controls are phenotypically normal and
have been previously shown to have minimal changes in global gene expression [26]. (A-F) Expression of TrkC, Runx3, and Etv1. TrkC and Runx3
immunoreactive neurons are reduced to less than 10% of controls. Small Etv1 immunoreactive neurons, most of which co-express Islet2, are
unaffected. (G, H) Neurons expressing TrkB persist in Brn3a
-/- mice at P0, but the distribution of the protein is markedly altered, with increased
expression in axons and less expression in discrete cell bodies. (I-R) Expression of nociceptor markers Runx1, TrkA and Ret. The absolute number
of Runx1 positive neurons is significantly decreased across the rostrocaudal extent of the ganglion (K, paired t-test, P = 0.001), and this loss is in
excess of the overall decrease in cell number as assayed by Islet1 expression (L, paired t-test, P = 0.0004). TrkA expression is markedly diminished
in the knockout (M, N). Small diameter neurons co-expressing Runx1 and Ret (O, arrows) are absent from the knockout, but a population of large
diameter Ret
+ neurons that are negative for Runx1 and TrkA, and may represent a class of mechanoreceptors, persist (O, P, arrowheads). HT,
heterozygote control; KO, knockout.
Dykes et al. Neural Development 2010, 5:3
http://www.neuraldevelopment.com/content/5/1/3
Page 6 of 18peptides are not [7]. The mature expression pattern of
these sensory markers is not complete until the second
postnatal week, but we were able to assess the expres-
sion of several of these factors in the TG of P0 Brn3a
-/-
mice.
The TG of Brn3a
-/- newborn mice showed a profound
reduction of most Runx1-dependent channels and
receptors (Figure 3A). Expression of TrpM8 was unde-
tectable, and Mrgprd, Mrgpra1, and Scn11a were mark-
edly reduced. In contrast, expression levels of mRNA for
the Runx1-independent neuropeptides CGRP and Sub-
stance P/Tachykinin 1 (SP/Tac1) were little changed
(Figure 3B), consistent with past results [16,17].
Although we have previously shown increased expres-
sion of somatostatin in the TG of Brn3a
-/- embryos at
E13.5 [26], in accordance with a previous study [16], we
found that somatostatin was not detectable in the wild-
type or knockout ganglion at P0 (data not shown).
Changes in the expression of some transcripts did not
closely parallel the effects of Runx1 deletion in the
DRG. The ATP receptor P2X3 is found primarily in
non-peptidergic nociceptors in the DRG, but associated
with a variety of sensory neuron types in the TG [41].
P2X3-expressing neurons are markedly reduced in
Runx1 knockout DRG, but little changed in the Brn3a
-/-
TG (Figure 3A). Expression of the acid-sensing receptor
Accn3/DRASIC, also found in a range of large and
small sensory neurons in the TG [42], is Runx1-inde-
pendent in the DRG and was markedly decreased in the
Brn3a
-/- TG (Figure 3B). These differences may be due
to the presence of distinct nociceptor populations in the
DRG and TG, or represent Runx1-independent Brn3a
targets (see Discussion).
T h eo n l ym e d i a t o ro fn o c i c e p t i o nf o u n dt os h o wa
marked increase in expression in the Brn3a
-/- TG was
the serotonin receptor subunit Htr3a (Figure 3C),
which, unlike other serotonin receptors, is a ligand
gated ion channel that forms functional pentameric
5HTR3 complexes with itself or Htr3b subunits [43]. It
is expressed by a distinct class of nociceptive neurons,
most of which do not express SP, and appear to mediate
persistent but not acute pain [28]. It may thus charac-
terize a ‘nonpeptidergic’ class of nociceptors, but these
results suggest that it is regulated very differently from
canonical non-peptidergic markers.
Brn3a is required for the initiation of Runx3 expression
and maintenance of TrkC
We next looked at the timing of the expression of TrkC
and Runx3 markers in Brn3a
-/- and control embryos to
determine at what point in the development of these
neurons Brn3a is required. TrkC is widely expressed in
the TG at E10.5, and overlaps TrkB at this stage (Figure
4A). It is clear that Brn3a is not required for the initia-
tion of TrkC expression because at E10.5 TrkC is
expressed appropriately in Brn3a
-/- embryos, and is co-
expressed with TrkB in a pattern similar to the wild
type (Figure 4B). In contrast, Runx3 is not expressed at
this stage in either genotype (Figure 4C, D).
By E12.5, TrkB- and TrkC-expressing neurons nor-
mally segregate into a non-overlapping pattern (Figure
4E). Runx3 is expressed in the trigeminal at this stage,
and its expression pattern is nearly congruent with that
of TrkC (Figure 4G). In Brn3a
-/- embryos, TrkB- and
TrkC-expressing neurons do not appropriately segregate
into distinct populations, and Runx3 expression is not
initiated (Figure 4F, H). Discrete populations of TrkB
and TrkC/Runx3 expressing neurons are maintained in
wild-type ganglia at E13.5 (Figure 4I, K), and throughout
development. In Brn3a
-/- embryos at E13.5, TrkB is
increased relative to controls (Figure 4J) and TrkC is
nearly undetectable (Figure 4J, L). In contrast, early-dif-
ferentiating Ret
+ neurons are undiminished in the Brn3a
knockout (Figure 4M-P). These early Ret
+ neurons do
not co-express TrkA or Runx1, either in control or
Brn3a
-/- TG, and probably constitute a subset of
mechanoreceptors [40].
Together these data suggest that permitting the initia-
tion of Runx3 expression is one of the primary roles of
Brn3a. The normal initial expression of TrkC in Brn3a
-/-
TG suggests that regulation of TrkC is a secondary
effect. Loss of Runx3 may lead to the failure of TrkB
and TrkC to segregate into distinct lineages, consistent
with previous work demonstrating that Runx3 represses
TrkB expression while promoting expression of TrkC
[23,44]. This is then followed by loss of TrkC expression
in all TrkB/C precursors by E13.5.
Brn3a is required for Runx1 expression and the
segregation of TrkA/TrkB expression in nociceptor
precursors
At E10.5, TrkA is co-expressed with TrkB (Figure 5A,
B), in a manner similar to TrkC. Co-expression of TrkA
and TrkB prior to E11.5 has been observed in prior stu-
dies [45]. To identify the stage at which TrkA and TrkB
become discrete, we examined embryos at half-day
developmental steps from E10.5 to E12.5, and observed
that TrkA/B are significantly co-expressed at E11.0, are
still co-localized in a small number of TG neurons at
E11.5, but are discrete by E12.0 (Additional file 5). At
E12.5 in the normal TG, TrkA and TrkB are expressed
in distinct neuronal populations (Figure 5E), but in the
Brn3a knockout these markers fail to segregate (Figure
5F). This led us to consider whether segregation of
TrkA/TrkB expression is regulated by Brn3a via Runx
activity, as is TrkB/TrkC expression.
In normal embryos, Runx1 is first detectable at E11.5
(Additional file 6). Runx1 expression is severely attenu-
ated in the TG of Brn3a
-/- embryos at E12.5 (Figure 5C,
D), and recovers only to a small extent later in
Dykes et al. Neural Development 2010, 5:3
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of the onset of Runx1 expression and of TrkA/B discri-
m i n a t i o n ,a sw e l la st h el o s so fR u n x 1a n dT r k A / Bd i s -
crimination in Brn3a knockouts, are consistent with a
role for Runx1 in the repression of TrkB in TrkA/B pre-
cursors. Further support for a role of Runx1 in restrict-
ing the expression of TrkB is derived from the
observation that a small number of neurons that main-
t a i nR u n x 1e x p r e s s i o ni nt h eB r n 3 ak n o c k o u ta tE 1 2 . 5
and E13.5 are TrkB negative (Figure 5D, H). These
results demonstrate that Runx1 and Runx3 play similar
roles downstream of Brn3a in discriminating sensory
subtypes.
A transactivator Brn3a construct provides insights into its
direct targets
Prior microarray studies of the sensory ganglia of Brn3a
knockout mice have revealed transcripts both increased
and decreased in the absence of this factor [13,26].
Figure 3 Expression of Runx1-dependent and Runx1-independent transcripts for receptors, channels and neuropeptides in the
Brn3a
-/- TG. The TG of Brn3a
-/- and control mice were examined for the expression of multiple sensory markers at P0, the last stage available
due to the neonatal death of the knockout mice. Coronal sections are shown except for Trpm8 and Scn11a, which are horizontal sections. (A)
Expression of transcripts showing Runx1-dependence in the DRG. (B) Expression of transcripts independent of Runx1 in the DRG. (C) Expression
of transcripts for which Runx1-dependence has not been characterized.
Dykes et al. Neural Development 2010, 5:3
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Page 8 of 18Figure 4 Early defects in specification of TrkC neurons in the Brn3a
-/- TG. The TG of Brn3a knockout and control embryos were examined
at various stages for the expression of TrkB, TrkC and Runx3. (A-D) At E10.5 TrkB and TrkC are extensively co-expressed in both genotypes.
Runx3 was not detected at this stage in either genotype. (E-H) At E12.5 TrkB and TrkC expression identify discrete subsets of neurons in control
ganglia (E), but in Brn3a knockout ganglia co-expression persists (F), and examples of the numerous co-expressing neurons are indicated by
arrowheads. Runx3 and TrkC are co-expressed in control ganglia (G), but Runx3 expression is not initiated in the knockout TG, and TrkC
expression is diminished (H). (I-L) At E13.5, TrkB expression is markedly expanded in knockout ganglia (J), and TrkC and Runx3 expression is
nearly absent (J, L). Rare remaining TrkC
+/Runx3
+ neurons in the knockout TG are indicated by arrows (J, L). (M-P) Early Ret
+ neurons at this
stage do not co-express TrkA or Runx1 in the control or knockout ganglia, and persist in Brn3a
-/- ganglia. Ret
+ neurons at this stage are likely to
represent a subset of mechanoreceptors; Ret
+ nociceptors are not detected until the perinatal period. Scale bar = 50 μM.
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for bHLH transcription factors that are expressed early
in sensory neurogenesis and subsequently repressed by
Brn3a [14], and a direct transcriptional activator func-
tion has not been demonstrated for Brn3a in vivo.T o
screen for novel direct targets, we employed the expres-
sion of a transgene in which the DNA-binding domain
of Brn3a is fused to a strong amino-terminal transactiva-
tion domain derived from the herpes virus protein
VP16. For genes on which Brn3a functions as a direct
repressor, VP16-Brn3a would be expected to phenocopy
the knockout because expression of a constitutive
transactivator should mimic the loss of a repressor.
However, for genes on which Brn3a functions as a direct
activator, if any, VP16-Brn3a would be expected to
induce changes in gene expression opposite to the loss-
of-function mutant.
We first tested the function of the VP16-Brn3a fusion
protein in heterologous cell transfection assays, where it
induced a >1,000-fold activation of a luciferase reporter
construct (Figure 6A). Transactivation was entirely
dependent on the presence of a Brn3a consensus bind-
ing site [29] in the reporter plasmid. A transgene was
then constructed containing VP16-Brn3a, an IRES
Figure 5 Defects in nociceptor specification in the Brn3a
-/- TG. The TG of Brn3a knockout and control embryos were examined at various
stages for the expression of TrkA, TrkB, and Runx1. (A, B) At E10.5, TrkA and TrkB are extensively co-expressed in control (A) and Brn3a knockout
(B) ganglia. Runx1 is not expressed at this stage. (C, D) At E12.5, Runx1 is expressed in control ganglia (C) but is markedly diminished in the
knockout (D). Arrows mark rare Runx1
+ cells. (E, F) At E13.5, TrkA and TrkB expressing neurons normally segregate into discrete populations (E)
but fail to do so in Brn3a knockout ganglia (F). Exposure time for TrkA in (F) is increased to reveal co-expression; see (I, J) for equal exposures.
Arrowheads in (F) indicate examples of numerous abnormal TrkA
+/TrkB
+ cells. (G, H) At E13.5, Runx1 expression is markedly diminished in the
knockout. The few Runx1
+ neurons detected at this stage do not express TrkB (H, arrows). Scale bar = 50 μM.
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ter (Figure 6B). This expression cassette was placed
downstream of regulatory sequences derived from the
mouse Brn3a locus that have previously been shown to
target expression specifically to sensory neurons
throughout the neural axis [21]. Transgenic founder
embryos were harvested at E13.5, and GFP expression
in the DRG was used to verify the specific expression of
the transgene in the sensory neurons of individual
embryos (Figure 6C). The DRG of the VP16-Brn3a
embryos appeared normal in size, and produced the
expected axonal projections into the periphery and the
superficial lamina of the spinal cord.
Trigeminal ganglia were isolated from those embryos
showing strong sensory GFP expression (Figure 6D),
and independent microarray analyses (Affymetrix 430v2
mouse microarray) were performed on TG from the
three embryos showing the highest expression of the
transgene by quantitative PCR. Three littermate
embryos, matched for developmental stage, were ana-
lyzed in parallel as controls, allowing a total of nine (3 ×
3) semi-independent comparisons between VP16-Brn3a
and control samples using the Affymetrix MAS5 analysis
software. The magnitude of the changes in gene expres-
sion in the VP16-Brn3a mouse were modest compared
to those seen in the knockout. The effects of VP16 mis-
expression may be limited because the transgene was
not expressed in all TG neurons, and because the VP16-
Brn3a protein must compete with endogenous Brn3a for
target gene site occupancy. Additional file 1 provides a
complete list of gene expression changes in the VP16-
Brn3a embryo for all transcripts showing a greater than
three-fold change in the Brn3a knockout. Those tran-
scripts with an increased (I) call in greater than half of
the nine two-way MAS5 comparisons are highlighted
and represent potential direct targets of regulation by
Brn3a.
We then plotted the changes in gene expression in the
VP16-Brn3a mouse against changes observed in Brn3a
knockout TG (Figure 6E), revealing similar regulation of
key developmental transcription factors (Figure 6F).
Because the direct effects of VP16-Brn3a result only in
gene activation, the decreased expression of any gene is
presumed to be an indirect effect. Thus, all transcripts
below the x-axis in this plot are probably not direct tar-
gets of Brn3a at this developmental stage, and notably
this group includes Runx1 and all the Trk-class
receptors.
Transcripts in the top right quadrant of Figure 6E
show higher than wild-type expression in both the
B r n 3 ak n o c k o u ta n di nt h eV P 1 6 - B r n 3 am o u s e( t h a ti s ,
the VP16 fusion phenocopies the knockout), indicative
of a role for Brn3a in the direct repression of these
genes. This group contains many transcription factors,
including the known directly repressed targets Neurod1
and Neurod4 [14]. Other potential targets of direct
repression revealed by this screen include Neurog1 (neu-
rogenin 1) and the homeodomain factor Irx2.
Those transcripts in the top left quadrant are
decreased in the knockout but activated by VP16-Brn3a
and are thus good candidates for genes directly activated
by Brn3a. Remarkably few genes show this relationship,
suggesting that Brn3a functions primarily as a repressor
at this stage. Two of the most prominent transcripts in
this category are Hes5 and Runx3, and Runx3 was
selected for further studies of direct regulation by Brn3a.
Identification of occupied Brn3a binding sites in the
Runx3 locus
Runx3 is a large gene locus consisting of six exons span-
ning 57 kb, and lying 183 kb from its nearest 5’ neigh-
bor, Syf2 ( F i g u r e7 A ) .W eh a v ep r e v i o u s l ye m p l o y e da
locus-wide ChIP assay to determine Brn3a binding sites
in the Neurod1 and Neurod4 loci [14]. However, the
size of the Runx3 locus and its flanking sequences make
this approach problematic. Instead we used existing
information about Brn3a DNA binding sites to identify
potential sites in the Runx3 locus that could then be
subsequently tested using EMSA and ChIP assays.
Brn3a is a homeodomain-containing transcription fac-
tor with a bipartite binding site, which in general binds
to sites containing two TAAT motifs in close proximity.
Brn3a has been shown to have an optimal binding site
of ATAATTAAT but also recognizes sequences with
conservative substitutions conforming either to the con-
sensus AT
A/TA
A/TT
A/TA To rh a v i n gas i n g l eb a s ed i f -
ference from the optimal site at specific positions [29].
Binding sites in the Neurod1 and Neurod4 loci occupied
by Brn3a in the developing TG have exactly matched
this consensus [14]. We searched the Runx3 locus for
potential binding sites within these parameters, and
identified ten candidate sites (Additional file 2). Two of
these sites are located within introns of the Runx3 gene,
while the remaining eight are located up to 173 kb
upstream of the Runx3 transcriptional start site. Brn3a
binding to the identified sites was tested in vitro using
EMSA with oligonucleotide probes and cell lysates from
Brn3a-transfected HEK293 cells. The three sites that
exhibited the strongest in vitro binding were located at
-173 kb, -94 kb and -25 kb relative to the Runx3 tran-
scription start site (Figure 7B).
Because we have previously shown that in vitro bind-
ing of Brn3a to a specific regulatory element is a neces-
sary but not sufficient requirement for in vivo site
occupancy [14], we next used ChIP to assay Brn3a bind-
ing to its Runx3 locus recognition sites in the TG. E13.5
was chosen for these assays, 1 to 2 days after the initia-
tion of Runx3 expression, because we reasoned that at
this time point regulators of Runx3 expression would
Dykes et al. Neural Development 2010, 5:3
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Page 11 of 18Figure 6 Sensory-specific expression of a VP16-Brn3a constitutive transcriptional activator reveals possible direct regulatory targets.
(A) Activation of transcription by VP16-Brn3a in transfection assays. Increased expression requires both the VP16-Brn3a protein and the presence
of a consensus Brn3a binding site (3× Brn3a cons) in the reporter gene construct. (B) Structure of the VP16-Brn3a transgene. A dicistronic
message encoding VP16-Brn3a and enhanced green fluorescent protein (eGFP) is driven by an 11-kb sensory enhancer from the Brn3a locus. (C)
Expression of eGFP in the E13.5 dorsal root ganglia (DRG) of VP16-Brn3a transgenic founders by direct GFP fluorescence (whole mount) and
immunofluorescence (sections). Appropriate axonal projections to the dorsal spinal cord (SC) are evident. The TG of these embryos were
harvested for array analysis. (D) RT-PCR assays of Brn3a-VP16 expression in TG dissected from transgenic embryos, normalized to
phosphoglycerate kinase (Pgk) expression. Embryos 11, 49, and 76 (asterisks) were selected for microarray analysis. (E) Microarray analysis of
changes in gene expression in VP16-Brn3a transgenic embryos at E13.5. Changes in gene expression in the VP16-Brn3a transgenic TG were
plotted (y-axis) against changes in the E13.5 Brn3a knockout (x axis). Only data for transcripts showing significantly increased or decreased
expression in the Brn3a
-/- TG relative to controls are shown, thus data points are missing from around the origin. For the entire group, the
correlation was weak (slope = 0.126, R
2 = 0.147), suggesting that many Brn3a targets are indirectly regulated. The microarray analyses of Brn3a
-/-
and control ganglia used for comparison purposes will be presented in detail elsewhere (Lanier et al., in preparation). (F) Changes in
transcription factor expression in E13.5 Brn3a knockout ganglia and VP16-Brn3a ganglia, and the number of change calls (out of nine possible
comparisons) for VP16-Brn3a versus control ganglia. ‘A’ indicates absent call. Neurod1 and Neurod4, previously shown to be directly repressed by
Brn3a, were activated by VP16-Brn3a. Runx3 and Hes5 are candidates for direct positive regulation by Brn3a (expression increased by VP16-Brn3a,
decreased in knockout), Neurog1, Insm1, Eya2, and Tcaf2b are further candidates for direct negative regulation (expression increased by VP16,
increased in knockout).
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Page 12 of 18Figure 7 Brn3a binds to regulatory sequences within the Runx3 locus. (A) Map of a 300-kb region of mouse chromosome 4 including the
Runx3 and Syf2 loci. The location of three sites (-173 kb, -94 kb and -25 kb) showing strong in vitro Brn3a binding are indicated (blue circles).
Also shown is an interspecies sequence alignment of a region within the proposed -94-kb enhancer, which contains a conserved consensus
Brn3a binding site (blue box) and additional conserved TAAT motifs (green boxes) that represent additional potential homeodomain
transcription factor binding sites. (B) EMSA for Brn3a binding to sites identified by sequence search; assays for the three sites exhibiting
strongest binding are shown. P, probe only; -, probe incubated with protein extract from untransfected HEK cells; +, probe incubated with
protein extract from HEK cells transfected with a Brn3a expression construct; Ab, Brn3a-transfected cell extract plus supershifting anti-Brn3a
antibody; arrow, shifted band; asterisk, supershifted band. Multiple shifted bands may indicate cooperative binding of Brn3a to adjacent sites [56].
(C) ChIP profiling of in vivo Brn3a binding to the Runx3 locus in E13.5 TG. Two or three primer pairs were made to the regions containing each
of the nine potential Brn3a binding sites identified by sequence search (Additional file 4). Quantitative PCR assays were performed on
immunoprecipitated chromatin selected with an anti-Brn3a antibody from three independent samples. Fold enrichment for selected/unselected
was calculated using the cycle threshold difference method (Methods). Graph shows the mean + standard error for three assays of independent
samples. As expected, binding is not observed at the promoter region of the Alb (serum albumin) locus, which is not transcribed in neurons and
does not contain Brn3a binding sites [14]. Unpaired t-test for selection at -94-kb site: n = 8 experimental assays, n = 13 alb locus controls, P =7
×1 0
-5. (D) ChIP profiling of histone H3 acetylation at the Runx3 locus. Assays were performed as described in (C), with an antibody recognizing
lysine 9/14 acetyl histone H3. Increased acetylation in the vicinity of the Brn3a binding site at -94 kb suggests an open conformation of
chromatin at this location.
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pairs were designed to the immediate vicinity of the ten
potential Brn3a sites (Additional file 4), and enrichment
of the target sequences in Brn3a-selected samples rela-
tive to an unselected (input) sample was determined
using the cycle threshold difference method [32]. Five
primer sets designed to the Alb locus (serum albumin),
which is silent in the sensory ganglia and does not con-
tain Brn3a binding sites [14], were used to normalize
the enrichment values from Runx3. Additional control
primers were designed to sequences within the Syf2
gene, which lies 183 kb 5’ to the of Runx3 transcrip-
tional start site (Figure 7A).
The majority of sites tested gave ChIP enrichment
values of two-fold or less relative to the Alb locus, indi-
cating that these sites are probably not occupied by
Brn3a in vivo. The Syf2 primers also yielded enrichment
values close to baseline. Notably, a site at -25 kb, which
bound Brn3a efficiently in vitro,d i dn o ta p p e a rt ob e
occupied in vivo. Enrichment was observed for some
primers encompassing the binding sites at -173 kb and
-72 kb, but consistent selection was observed only for
the compound binding site located at -94 kb, which
showed a mean enrichment of six-fold. The region
encompassing this site shows strong cross-species con-
servation among several eutherian mammals, opossum,
and chicken (Figure 7A). In addition, the region con-
tains multiple TAAT motifs that may accommodate
multimeric Brn3a binding or transcriptional partners.
Regulatory regions of chromosomes are known to be
associated with histone modifications, including acetyla-
tion of H3 subunits, which are believed to induce an
open form of chromatin accessible to transcription fac-
tors [46,47]. In prior work we have demonstrated that
binding of Brn3a autoregulatory regions in the Pou4f1
locus and to downstream target gene loci is highly cor-
related with H3 acetylation [14]. We therefore examined
the Runx3 locus and control loci by ChIP to assess the
histone H3 acetylation state of the potential Brn3a bind-
ing sites (Figure 7D). Peak enrichment (5.2-fold) was
observed at the identified binding site at -94 kb. In con-
trast, the region containing the Brn3a consensus site at
-25 kb was not significantly H3 acetylated, which may
explain why it is not occupied by Brn3a.
Discussion
Cell loss in the Brn3a knockout TG
The results presented here for the populations of TG
neurons present at birth in Brn3a
-/- mice differ some-
what from prior studies. We find approximately 72% of
T Gn e u r o n sa r ep r e s e n ta tb i r t h ,c o m p a r e dt om o r e
profound cell losses noted by others [10,18,33]. Our
results for stage-specific changes in neurotrophin
expression are consistent with prior studies showing
early loss of TrkC expression [11,18], abnormally
increased expression of TrkB at E12.5 to E13.5, and late
loss of TrkA [18]. However, prior studies have reported
nearly complete elimination of the TrkB
+ population by
birth [18,33], whereas here we observe a significant
population of TrkB
+ neurons, exhibiting abnormal mor-
phology, persisting at P0 (Figure 2H). Thus, the most
likely explanation for the relative preservation of cell
number in the Brn3a
-/- TG observed here is the delayed
elimination of an abnormal TrkB
+ population of neu-
rons, perhaps due to differences in genetic background.
We infer that if Brn3a
-/- mice survived after birth, the
results of these studies would converge in the early
postnatal period.
Brn3a is required for sensory subtype differentiation, via
promotion of Runx expression
Early sensory neurons express multiple Trk receptors,
and depend on the activity of Runx transcription factors
to refine this non-specific pattern into mutually exclu-
sive TrkA, TrkB and TrkC expression. For example,
TrkC
+ DRG proprioceptors develop from TrkB
+/TrkC
+
precursors, a subset of which initiate expression of
Runx3, followed by downregulation of TrkB and exclu-
sive expression of TrkC in the mature neuron [23]. In
Runx3
-/- embryos, TrkC expression is lost, coupled with
an increase in TrkB
+ neurons, while mis-expression of
Runx3 promotes TrkC and represses TrkB [23,34].
Runx3 repression of TrkB expression appears to be
mediated by direct binding of Runx3 to the Ntrk2 locus
[44].
Runx1 is initially co-expressed with TrkA in the noci-
ceptor lineage [7,8], and initiation of TrkA expression is
not dependent on Runx1 [48]. The emphasis of recent
work on Runx1 has been on its role in late nociceptor
development, and the effect of the loss of Runx1 on the
initial discrimination of TrkA/TrkB-expressing precur-
sors has not been reported. However, ectopic expression
of Runx1 in E12.5 DRG represses TrkB expression, pro-
motes both TrkA and TrkC, and appears to be inter-
changeable with Runx3 in these effects [23]. Thus, it is
likely that both Runx1 and Runx3 function to repress
TrkB and promote the exclusive expression of TrkA and
TrkC in nociceptors and proprioceptors, respectively.
The Brn3a
-/- TG exhibits a profound decrease in the
expression of both Runx3 and Runx1, and failure to
appropriately activate Runx expression can account for
much of the early developmental phenotype of the
Brn3a
-/- TG. In control TG, Runx3 expression follows
TrkC by one developmental day. In Brn3a
-/- TG, TrkC
expression is initiated normally, although Runx3 is
never expressed, indicating that Runx3 is necessary for
the maintenance but not the onset of TrkC expression,
consistent with prior results in Runx3
-/- embryos [34].
By E13.5, when the expression of TrkA/TrkB/TrkC
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of TrkB in the Brn3a knockout. The abnormally persis-
tent co-expression of TrkB and TrkC in the Brn3a
-/-
TG, and the subsequent loss of TrkC expression, are all
consistent with effects mediated by Runx3.
Brn3a
-/- TG neurons also exhibit abnormal persistence
of the co-expression of TrkA and TrkB, and subsequent
loss of TrkA expression. Given the ability of Runx1 to
repress TrkB [23], it is very likely that the failure to dis-
criminate TrkA
+ and TrkB
+ neural identities in the
Brn3a
-/- TG is due to the loss of Runx1 function, and
that Runx1 performs an analogous function in nocicep-
tor precursors to that of Runx3 in the TrkC lineage.
TrkB expression may represent a default pathway
adopted by trigeminal neurons in the absence of Runx-
mediated repression.
Nakamura et al.[ 4 9 ]h a v eo b s e r v e dt h a tt h eD R Go f
Runx3 knockouts lack early TrkC
+ proprioceptors, but
that some TrkC
+ neurons appear after E14.5. These late
TrkC neurons project cutaneously and co-express TrkA
and CGRP. No significant late appearance of TrkC-
expressing neurons was observed in the Brn3a
-/- TG,
a n dt h er a r eT r k Cn e u r o n so b s e r v e da tP 0a r eR u n x 3
+,
and have large soma characteristic of proprioceptors or
mechanoreceptors (Figure 2B). This suggests that Runx1
promotes TrkC expression in late-developing cutaneous
neurons in Runx3 knockouts, but not in Brn3a
-/- ganglia
in which both Runx1 and Runx3 expression are severely
attenuated.
Brn3a is required for the expression of a battery of
functional genes in differentiated nociceptors
Mature nociceptors can be broadly differentiated into
peptidergic and non-peptidergic classes, with distinct
nociceptive functions and central projections [50]. Pep-
tidergic nociceptors express sensory neuropeptides
such as CGRP and SP, while non-peptidergic nocicep-
tors are characterized by the cell-surface marker IB4
[2,3]. The maturation of these nociceptor phenotypes
is not complete until the second postnatal week.
Recent work has shown that peptidergic nociceptors
maintain postnatal expression of TrkA, while non-pep-
tidergic neurons make a late, Runx1-dependent switch
from TrkA to Ret expression [7]. The expression of
multiple sensory markers, including Trpa1, TrpC3,
Trpm8, Scn11a and several members of the Mrg
family, are Runx1-dependent in the DRG. Expression
of Trpv1 and Trpv2 is affected only in a subset of
high-expressing neurons, while SP, CGRP, Accn3 and
the mu opioid receptor (MOR) exhibit normal or
increased expression in Runx1 knockouts [7,48]. The
role of Runx1 in determining the final nociceptor gene
expression profile is complex, in that the loss of Runx1
favors neuropeptide expression, and CGRP is repressed
by ectopic expression of Runx1 [23], yet some
functional genes associated with the peptidergic phe-
notype, such as Trpm8 and TrpA1, are Runx1-depen-
dent [3].
The TG of Brn3a
-/- newborn mice exhibit marked
reduction in Trpm8, Mrga1, Mrgd and Scn11a, while
CGRP and SP are minimally affected. These results are
consistent with the hypothesis that much of the
Brn3a
-/- nociceptor phenotype is mediated by the loss
of Runx1. However, differences were noted between
the Brn3a
-/- TG and published results for the Runx1
knockout for the purine receptor P2X3,w h i c hi s
reduced in Runx1
-/- DRG but shows little change in
the Brn3a
-/- TG, and the acid-sensitive channel Accn3,
which is increased in Runx1
-/- DRG but decreased in
the Brn3a knockout. P2X3-expressing sensory neurons
are heterogeneous in the TG, and include medium and
large neurons with myelinated axons as well as the
IB4-positive non-peptidergic nociceptors that predomi-
nate in the DRG [41]. Thus, it is likely that differences
between the Brn3a and Runx1 knockouts with respect
to P2X3 expression result from differing effects on dis-
tinct populations of P2X3
+ neurons in the TG and
DRG. Accn3 is also expressed in small peptidergic and
non-peptidergic neurons and as well as mechanorecp-
tors [42], and may also identify different cell popula-
tions in the DRG and TG.
Ichikawa et al. [17] have previously reported, consis-
tent with the present study, that CGRP expression is
minimally changed in the Brn3a
-/- TG. They have also
shown that mu opioid receptor (MOR) expression is
increased, and that Trpv1 expression is present in small-
and medium-sized neurons, and is unchanged [16].
These results are also consistent with changes mediated
by the loss of Runx1 in Brn3a knockouts.
Runx1-mediated effects are not sufficient to explain
the loss of TrkA expression in the Brn3a
-/- TG. Early
expression of TrkA is normal in the Brn3a knockouts
(Figure 5A, B) but begins to decline at mid-gestation
and it is markedly reduced by birth in the TG (Figure
2N) [18] and in the DRG [11]. In contrast, Runx1
-/-
DRG show increased numbers of TrkA
+ neurons [7].
Brn3a has been reported to directly regulate the expres-
sion of TrkA [33,39,51], and this may occur indepen-
dently of the Runx1-mediated changes in gene
expression.
Brn3a directly regulates Runx3 expression
Nearly complete loss of Runx3 in the Brn3a
-/- TG from
the time of normal onset of its expression is suggestive
of direct regulation. Runx3 is one of a small number
of genes activated by VP16-Brn3a that are also
decreased in the Brn3a knockout, indicating that Brn3a
acts primarily as a transcriptional repressor in the
early phase of TG development. Brn3a has previously
been shown to directly repress the expression of
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has, to date, only been demonstrated in cell transfec-
tion models [21,29].
Here we have shown that Brn3a interacts directly in
vivo with an enhancer element located approximately
94 kb upstream of the Runx3 transcriptional start site.
Although this enhancer is distant from the transcrip-
tion start site, it is evolutionarily conserved and bears
histone modifications associated with open chromatin
that have been found at other in vivo Brn3a binding
sites [14]. It is not unusual for regulatory elements in
developmental genes to be located at large distances
from their respective transcription start sites. Examples
include regulatory elements 400 kb from the promoter
of sonic hedgehog (Shh) [52] and an enhancer element
210 kb downstream of the Pax6 promoter [53]. ChIP
assays provide less consiste n te v i d e n c ef o rB r n 3 ab i n d -
ing to two other regions of the Runx3 locus, and other
sites may exist that were not predicted by the consen-
sus recognition sequence used and thus were not
tested in this study.
Pan-sensory transcription factors and subtype
specification
Because it is a pan-sensory transcription factor, Brn3a is
not a good candidate for the initial specification of sen-
sory subtypes. Instead, Brn3a allows trigeminal neurons
to progress from a ground state in which all three neu-
rotrophin receptors are co-expressed to a differentiated
state in which they are discrete. Brn3a creates a permis-
sive condition for subtype specification by promoting
Runx1 and Runx3 expression, which then refine sensory
neuron phenotypes by repressing TrkB in prospective
TrkA- and TrkC-expressing neurons, respectively.
Although Brn3a binds directly to a Runx3 enhancer ele-
ment, it is clear that this is a necessary but not sufficient
condition for the initiation of Runx3 expression since
Brn3a is widely expressed at the onset of Runx3 expres-
sion, yet Runx3 is only initiated in a subset of Brn3a
neurons. It is highly likely that other signals and tran-
scription factors are necessary to confer specificity on
Runx3 activation by Brn3a.
The essential role of pan-sensory transcription factors
in subtype specification is underscored by the related
roles of two other factors in sensory development, the
LIM-homeodomain factor Islet1 and the zinc finger pro-
tein Klf7, which, like Brn3a, are expressed in all or
nearly all sensory neurons prior to E12.5 [9,33]. The
DRG of Islet1 conditional knockout mice fail to initiate
R u n x 1e x p r e s s i o n .H o w e v e r ,u n l i k eB r n 3 ak n o c k o u t s ,
there is a marked decrease in DRG cell number by
E13.5. Large Runx3
+/TrkC
+ proprioceptors are main-
tained in the knockouts, apparently because Runx3
+
neurons downregulate Islet1 expression at an early
developmental stage and subsequently develop by an
Islet1-independent pathway. Klf7, in contrast, does not
appear to be necessary for the initial segregation of sen-
sory subtypes, but instead works synergistically with
Brn3a to maintain TrkA expression from mid-gestation
onward [33]. Brn3a, Islet1, and Klf7 may functionally
interact, but are regulated independently, as Brn3a and
Islet1 do not regulate one another’s expression [54], nor
do Brn3a and Klf7 [33]. Together these results fulfill an
early prediction that pan-sensory transcription factors
would be shown to have pivotal roles in sensory neuron
development [55].
Conclusions
Prior work has shown that Brn3a is necessary to termi-
nate the expression of early neurogenic transcription
factors such as Neurod1 and Neurod4 in the develop-
ing TG. Here we show that Brn3a also plays a role in
sensory subtype specification by promoting the expres-
sion of Runx1 and Runx3 in E11.5 to E13.5 ganglia. In
Brn3a knockout TG the Runx factors are markedly
downregulated, leading to a failure to repress TrkB
expression in TrkA- and TrkC-expressing neurons. At
birth, the TG of Brn3a knockout mice have multiple
defects in the expression of sensory neurotransmitters,
channels and receptors, several of which are consistent
with known effects of the Runx factors, but some of
which are likely mediated by other transcriptional
effects of Brn3a. Brn3a activation of the Runx3 gene
appears to be mediated through direct binding to con-
served upstream regulatory elements, constituting the
first verified direct transactivator function for this
factor.
Additional file 1: Table S1. (A) Potential targets of direct Brn3a
repression: VP16 activation of transcripts increased more than three-fold
in Brn3a knockouts. (B) Potential targets of direct Brn3a activation: VP16
activation of transcripts increased more than three-fold in Brn3a
knockouts.
Click here for file
[http://www.biomedcentral.com/content/supplementary/1749-8104-5-3-
S1.PDF]
Additional file 2: Table S2. Probes used for Runx3 locus EMSA.
Click here for file
[http://www.biomedcentral.com/content/supplementary/1749-8104-5-3-
S2.PDF]
Additional file 3: Table S3. Quantitative PCR primers used in the
chromatin precipitation assay of the Runx3 locus.
Click here for file
[http://www.biomedcentral.com/content/supplementary/1749-8104-5-3-
S3.PDF]
Additional file 4: Figure S1: Expression of TrkB mRNA at P0. Brn3a
+/+
and Brn3a
-/- newborn mice were harvested at P0 and sectioned in the
horizontal plane. In situ hybridization for TrkB mRNA shows that TrkB
expression is reduced, but present at this stage, consistent with
immunofluorescence data for TrkB protein.
Click here for file
[http://www.biomedcentral.com/content/supplementary/1749-8104-5-3-
S4.JPEG]
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Page 16 of 18Additional file 5: Figure S2: Developmental segregation of TrkA and
TrkB expression. The TG of control embryos were examined at E11,
E11.5, and E12.0 in the horizontal plane. TrkA/B immunoreactive cells
could no longer be detected at E12. Arrows indicate position of
representative TrkA/B co-expressing cells.
Click here for file
[http://www.biomedcentral.com/content/supplementary/1749-8104-5-3-
S5.JPEG]
Additional file 6: Figure S3: Onset of Runx1 expression in the TG.
The TG of control embryos were examined at E11, E11.5, E12 and E12.5
in the horizontal plane. Runx1 immunoreactivity was first detected at
E11.5. At this stage occasional cells were observed which co-expressed
Runx1 and TrkB (arrows), but co-expression was transient. Very bright
cells indicated by arrowheads are blood/vascular artifacts.
Click here for file
[http://www.biomedcentral.com/content/supplementary/1749-8104-5-3-
S6.JPEG]
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